Literature DB >> 6701452

Reference values for CSF-IgM, CSF-IgM/S-IgM ratio and IgM index, and its application to patients with multiple sclerosis and aseptic meningoencephalitis.

P Forsberg, A Henriksson, H Link, S Ohman.   

Abstract

Immunoglobulin M (IgM) concentrations were determined in cerebrospinal fluid (CSF) and serum (S) by enzyme-linked immunosorbent assay (ELISA). In 52 reference subjects, the upper reference limit was 0.46 mg/l for CSF-IgM, 0.32 X 10(-3) for CSF-IgM/S-IgM ratio, and 0.061 for IgM index equal to CSF-IgM X S-albumin/S-IgM X CSF-albumin ratio. No correlation to age over 15-85 years was found for any of these variables. Among 22 patients with aseptic meningoencephalitis (AM) elevated values of CSF-IgM were found in 68%, CSF-IgM/S-IgM ratio in 73%, and IgM index in 73%. The corresponding values among 35 patients with multiple sclerosis (MS) were 66%, 60% and 63%. The differences in diagnostic sensitivities for the three IgM variables were not significant. Eleven of 16 AM patients and two of 22 with MS had elevated IgM index in the presence of normal IgG and IgA indices. Determination of IgM index should therefore be performed in suspected inflammatory nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6701452     DOI: 10.3109/00365518409083780

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  12 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

Review 3.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

4.  Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis.

Authors:  M J Walsh; J M Murray
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

5.  IgM, IgA and IgG producing cells in cerebrospinal fluid and peripheral blood in multiple sclerosis.

Authors:  A Henriksson; S Kam-Hansen; H Link
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

6.  Detecting immunoglobulin abnormalities in the cerebrospinal fluid (CSF): which methods are best for clinical purposes?

Authors:  M A Laurenzi; L Provinciali; A R Giovagnoli; V Busco Bocchini; L Paris; F Chiodi
Journal:  Ital J Neurol Sci       Date:  1987-06

7.  Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus.

Authors:  J Ernerudh; T Olsson; F Lindström; T Skogh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

8.  Acute and chronic neuroborreliosis with and without CNS involvement: a clinical, MRI, and HLA study of 27 cases.

Authors:  H Krüger; E Heim; B Schuknecht; S Scholz
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

9.  Meningoradiculitis and encephalomyelitis due to Borrelia burgdorferi: a follow-up study of 72 patients over 27 years.

Authors:  H Krüger; K Reuss; M Pulz; E Rohrbach; K W Pflughaupt; R Martin; H G Mertens
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

10.  Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients.

Authors:  K Frei; T P Leist; A Meager; P Gallo; D Leppert; R M Zinkernagel; A Fontana
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.